SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare informs about press release

10 Dec 2021 Evaluate

Cadila Healthcare has informed that it enclosed a copy of press release dated December 10, 2021 titled ‘Zydus announces EPICS-IIITM Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC’.

The above information is a part of company’s filings submitted to BSE

Zydus Lifesciences Share Price

1115.50 -6.90 (-0.61%)
30-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 2000.75
Dr. Reddys Labs. 1144.35
Cipla 1466.00
Lupin 2419.10
Zydus Lifesciences 1115.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: